领航医药生物科技中期报告 2023-2024

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)()(Stock Code399 ) INTERIM REPORT2023/24 29Condensed Consolidated Statement ofChanges in Equity31Condensed Consolidated Statement ofCash Flows32Notes to the Condensed ConsolidatedFinancial Statements 2Corporate Information 4Chairman’s Statement 6Management Discussion and Analysis 17Other Information Provided inAccordance with the Listing Rules 23Condensed Consolidated Statementof Profit or Loss and OtherComprehensive Income 26Condensed Consolidated Statement ofFinancial Position Corporate Information公司資料 BOARD OF DIRECTORSExecutive DirectorsGao Yuan XingTang RongCheng Tak Yiu Non-executive DirectorsJiang Nian(Chairman)Xiao YanWu Yanmin Independent non-executive DirectorsChen WeijunWang RongliangChen Jinzhong Audit CommitteeChen Weijun(Chairman)Wang RongliangChen Jinzhong Remuneration CommitteeWang Rongliang(Chairman)Jiang NianChen Jinzhong Nomination CommitteeJiang Nian(Chairman)Wang RongliangChen Jinzhong HONORARY CHAIRMANMao Yumin COMPANY SECRETARYPoon Hon Yin Clarendon House2 Church StreetHamilton HM 11, Bermuda REGISTERED OFFICEClarendon House2 Church StreetHamilton HM 11, Bermuda Corporate Information公司資料 PRINCIPAL PLACE OF BUSINESS INHONG KONG Unit 2002, 20th floorOn Hong Commercial Building145 Hennessy RoadWan Chai, Hong Kong 145202002 PRINCIPAL SHARE REGISTRAR ANDTRANSFER AGENT Conyers Corporate Services(Bermuda) LimitedClarendon House2 Church StreetHamilton HM 11, Bermuda Conyers Corporate Services(Bermuda) LimitedClarendon House2 Church StreetHamilton HM 11, Bermuda 1617 BRANCH SHARE REGISTRAR ANDTRANSFER AGENT IN HONG KONG Tricor Tengis Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong AUDITORS 810 Elite Partners CPA Limited10/F, 8 Observatory RoadTsim Sha Tsui, KowloonHong Kong PRINCIPAL BANKERBank of Communications Co., Ltd. STOCK CODE399 399 www.ipb.asiawww.irasia.com/listco/hk/ipb COMPANY WEBSITE www.ipb.asiawww.irasia.com/listco/hk/ipb Chairman’s Statement主席報告 Dear Shareholders, On behalf of the board (the “Board”) of directors (the“Directors”) of Innovative Pharmaceutical Biotech Limited,(the “Company”, together with its subsidiaries, the “Group”),I hereby present to all shareholders of the Company (the“Shareholders”) the unaudited consolidated financial resultsof the Group for the six months ended 30 September2023 (the “Financial Period”) and the six months ended 30September 2022 (the “Previous Financial Period”). The Group only recorded revenue of approximately HK$3.7million for the Financial Period, a decrease of approximately9.7% in revenue from approximately HK$4.1 million asrecorded in the Previous Financial Period. 3,700,0004,100,0009.7% The Company reported a profit for the Period amounted toapproximately HK$193.7 million, as compared with the lossfor the Previous Financial Period amounted to approximatelyHK$115.7 million. It is due to the Company completed thethird amendment of the convertible bond with principalamount of HK$715 million issued by the Company duringthe Financial Period, an amount of approximately HK$330.3million non-cash item was credited into the incomestatement. 193,700,000115,700,000715,000,000330,300,000 Chairman’s Statement主席報告 OUTLOOK B300 The Group also engages in development of a technologythat would allow insulin to be administered orally. Thetechnology is still in the research and development stage.The Group has commenced the part B, Phase III of theclinical trial in August 2020 which is typically consideredas the final stage of clinical trial before commercialization.Currently, about 300 patients have participated in theclinical trial. The Group will use its best endeavours tocommercialise the product by the first quarter of 2025. The Company continues to actively pursue and reviewcooperation, joint ventures, and investments with suitablepartners and will continue to focus on improving theGroup’s attractiveness and profitability as necessary toenhance shareholder returns and the sustainable long-termdevelopment of the Group as a whole. APPRECIATION On behalf of all the members of the Board, I would liketo take this opportunity to express my gratitude to theShareholders and business partners of the Group for theircontinued support and trust during the past years, and mymost sincere appreciation to the directors, management,and staff at all levels for their dedication, hard work, andcontributions to the Group. Jiang NianChairmanShanghai, 29 November 2023 Management Discussion and Analysis管理層討論及分析 GROUP RESULTS 3,700,0004,100,0009.7%193,700,000115,700,000330,300,000 Revenue of the Group for the Financial Period amountedto approximately HK$3.7 million, representing a decreaseof approximately 9.7% as compared with the total revenueof approximately HK$4.1 million that was recorded inthe Previous Financial Period. The decrease was mainlyattributable to the decrease in business of the tradingof beauty equipment a